Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation

Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1500-1502. doi: 10.2215/CJN.0000000000000221. Epub 2023 Jun 14.

Authors

Hiddo J L Heerspink¹, Stefan Berger², Ron T Gansevoort²; Renal Life Cycle Trial Investigators

Collaborators

Renal Life Cycle Trial Investigators:
Aiko de Vries, Alferso Abrahams, Jeroen van der Net, Marc Hemmelder, Marc Vervloet, Rob van Kruijsdijk, Dirk Kuyper, Clare Arnott, Sunil Badve, Christoph Wanner

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
² Division Nephrology, Department Internal Medicine, University of Groningen, Groningen, The Netherlands.

PMID: 37314770
PMCID: PMC10637452 (available on 2024-11-01)
DOI: 10.2215/CJN.0000000000000221

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Kidney Transplantation*
Renal Dialysis
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / therapy
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents